BioAtla (NASDAQ:BCAB) Trading Down 4.6% – Time to Sell?

Shares of BioAtla, Inc. (NASDAQ:BCAB) fell 4.6% on Friday . The stock traded as low as $3.30 and last traded at $3.33. 113,187 shares traded hands during mid-day trading, an increase of 156% from the average session volume of 44,150 shares. The stock had previously closed at $3.49.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BCAB. Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a report on Wednesday. Wall Street Zen raised BioAtla to a “hold” rating in a report on Saturday, April 11th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $200.00.

BioAtla Trading Down 4.6%

The firm has a market cap of $5.53 million, a price-to-earnings ratio of -0.08 and a beta of 0.79. The stock has a fifty day moving average price of $4.75 and a 200 day moving average price of $16.43.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Friday, May 15th. The company reported ($4.22) EPS for the quarter, beating analysts’ consensus estimates of ($10.00) by $5.78.

Institutional Trading of BioAtla

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after buying an additional 162,647 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after acquiring an additional 1,531,994 shares during the last quarter. Marshall Wace LLP bought a new position in BioAtla during the fourth quarter worth $508,000. Millennium Management LLC raised its stake in BioAtla by 123.4% during the 4th quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after purchasing an additional 421,072 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after purchasing an additional 123,597 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.